Valerio Therapeutics (FRA:C4X) Net Issuance of Debt : €-1.22 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Valerio Therapeutics Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Valerio Therapeutics's net issuance of debt for the six months ended in Dec. 2023 was €-0.67 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.22 Mil.

Valerio Therapeutics Net Issuance of Debt Historical Data

The historical data trend for Valerio Therapeutics's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valerio Therapeutics Net Issuance of Debt Chart

Valerio Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Debt

Get a 7-Day Free Trial

-2.73

-3.09

2.62

-1.51

-1.22

Valerio Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Issuance of Debt	Get a 7-Day Free Trial															-1.18	2.34	-3.86	-0.55	-0.67

Valerio Therapeutics Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-1.22 Mil.

Valerio Therapeutics Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Valerio Therapeutics's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Valerio Therapeutics (FRA:C4X) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valerio Therapeutics (FRA:C4X) » Definitions » Net Issuance of Debt

Comparable Companies

Traded in Other Exchanges

ALVIO:France

Address

49 Boulevard du General, Martial Valin, Paris, FRA, 75015

Website

https://www.valeriotx.com

Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.

Valerio Therapeutics (FRA:C4X) Headlines

No Headlines